Open AccessRole of sodium-glucose co-transporter-2 inhibitors in the management of heart failure in patients with diabetes mellitus
Author(s) -
Stelina Alkagiet,
Κωνσταντίνος Τζιόμαλος
Publication year - 2020
Publication title -
world journal of diabetes
Language(s) - English
Resource type - Journals
ISSN - 1948-9358
DOI - 10.4239/wjd.v11.i5.150
Subject(s) - medicine , diabetes mellitus , heart failure , ejection fraction , context (archaeology) , type 2 diabetes mellitus , placebo , cardiology , randomized controlled trial , endocrinology , paleontology , alternative medicine , pathology , biology
Heart failure (HF) is a major complication of diabetes mellitus (DM). Patients with DM have considerably higher risk for HF than non-diabetic subjects and HF is also more severe in the former. Given the rising prevalence of DM, the management of HF in diabetic patients has become the focus of increased attention. In this context, the findings of several randomized, placebo-controlled trials that evaluated the effects of sodium-glucose co-transporter-2 inhibitors on the risk of hospitalization for HF in patients with type 2 DM represent a paradigm shift in the management of HF. These agents consistently reduced the risk of hospitalization for HF both in patients with and in those without HF. These benefits appear to be partly independent from glucose-lowering and have also been reported in patients without DM. However, there are more limited data regarding the benefit of sodium-glucose co-transporter-2 inhibitors in patients with HF and preserved left ventricular ejection fraction, which is the commonest type of HF in diabetic patients.